Promoting Quality in Drug Manufacturing

Wechsler,Jill;

CONTINUE TO SITE

OR WAIT null SECS

Spotlight

COVID-19 Update Analytics Dosage Forms Drug Development Manufacturing Outsourcing Quality Systems

COVID-19 UpdateAnalyticsDosage FormsDrug DevelopmentManufacturingOutsourcingQuality Systems

Topic

View More Analytical Method Development APIs Aseptic Processing Biologic Drugs Drug Delivery Equipment Excipients Formulation Packaging Process Control/PAT Process Development QA/QC Regulatory Action Supply Chain

Analytical Method DevelopmentAPIsAseptic ProcessingBiologic DrugsDrug DeliveryEquipmentExcipientsFormulationPackagingProcess Control/PATProcess DevelopmentQA/QCRegulatory ActionSupply Chain

News

All News Top News Industry News Bio/Pharma News Supplier News News from Europe Events

All NewsTop NewsIndustry NewsBio/Pharma NewsSupplier NewsNews from EuropeEvents

Publications

All Publications PharmTech PharmTech Europe

All PublicationsPharmTechPharmTech Europe

Resources

Front & Center Pharma Insights Sponsored eBooks Sponsored Podcasts Sponsored Videos Whitepapers

Front & CenterPharma InsightsSponsored eBooksSponsored PodcastsSponsored VideosWhitepapers

Webcasts Marketplace

Multimedia

Drug Digest Videos Drug Solutions Podcast

Drug Digest VideosDrug Solutions Podcast

Enewsletters Magazine North America Magazine Europe

EnewslettersMagazine North AmericaMagazine Europe

About Us
Advertise
Contact Us
Editorial Info
Editorial Contacts
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

Spotlight

COVID-19 Update
Analytics
Dosage Forms
Drug Development
Manufacturing
Outsourcing
Quality Systems

TopicSee All >

Analytical Method Development
APIs
Aseptic Processing
Biologic Drugs
Drug Delivery
Equipment
Excipients
Formulation
Packaging
Process Control/PAT
Process Development
QA/QC
Regulatory Action
Supply Chain

About Us
Advertise
Contact Us
Editorial Info
Editorial Contacts
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

Promoting Quality in Drug Manufacturing

September 2, 2004

Jill Wechsler

Pharmaceutical Technology, Pharmaceutical Technology-09-02-2004, Volume 28, Issue 9

FDA is re-engineering the CMC review process for innovator and generic drugs and backing risk-based ICH quality standards.

Novartis to Invest $250 Million for R&D of Neglected Tropical Diseases

GSK Announces £1 Billion R&D Investment in Fighting Infectious Diseases in Lower-Income Countries

FDA Leaders Seek to Build Public Trust in Science and Gain Support for Regulation